Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014–2022 in Pirkanmaa, Finland—an observational study
Therapeutic Advances in Urology · 2026-05 · 18
DOI: 10.1177/17562872261451289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Urology, online erschienen am 27.05.2026. Verfasst von Mikko Moisander und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Syöpäsäätiö, Pfizer Oy.
Abstract (Originalsprache)
Background
The prognosis of patients with metastatic prostate cancer (mPC) has changed profoundly in recent years. However, observational studies are required to understand the real-world outcomes of patients with mPC.
Objectives
In this retrospective single-center observational study, we aimed to describe characteristics, treatments, and outcomes of patients with mPC in Pirkanmaa Hospital District (PHD), Finland, an area with a population of 0.5 million (10% of the Finnish population).
Design
The incident patients with mPC treated in PHD during 2014–2022 were identified and stratified into patients with metastatic hormone-sensitive PC (mHSPC) and castration-resistant disease PC (mCRPC).
Methods
Patients with mPC were identified from electronic healthcare data using diagnoses, treatments, procedures, and patient texts. Data on demographics, diagnoses, procedures, treatments, laboratory and pathology tests, and specialized healthcare contacts were collected from specialty care records. Due to changes in treatment practices over time, treatments and outcomes were analyzed in different time periods (mHSPC: 2014–2016 and 2017–2022, mCRPC: 2014–2017 and 2018–2022).
Results
In total, 1083 incident patients with mPC were identified, of which 88% received treatment indicated for mPC. Out of the 795 patients with mHSPC, and 558 patients with mCRPC, 84% ( N = 668) and 95% ( N = 532) received treatment, respectively. The median overall survival (mOS) for all treated patients was 40.1 months. The mOS of treated patients with mHSPC increased from 32.6 months during 2014–2016 to 54.6 months during 2017–2022.
Conclusion
Since the approval of enzalutamide as a first-line treatment for mCRPC, it has become the most common first-line treatment for mCRPC in PHD. Novel therapeutics, including docetaxel, enzalutamide, and abiraterone, have been adapted into clinical practice and are being used at earlier phases of the disease. Changes in treatment practices correlate with improved outcomes in patients with mHSPC in the PHD area.
Trial registration
ClinicalTrials.gov NCT05701007.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Department of Oncology, TAYS Cancer Centre, Tampere University Hospital, Tampere University, Tampere, Finland.
- Medaffcon Oy, Espoo, Finland.
- Pfizer Oy, Helsinki, Finland.
- Faculty of Medicine and Health Technology, Tampere University, PO Box 100, Tampere 33014, Finland.
- Department of Urology, TAYS Cancer Centre, Tampere, Finland.
ORCID-Profile: Olivia Hölsä, Kaisa Teittinen, Kai Kysenius, Mikko Kosunen, Leena Lehmus
Förderung
- Research Council of Finland
- Syöpäsäätiö
- Pfizer Oy
- nordic cancer union
Zitieren
APA
Moisander, M., Hölsä, O., Teittinen, K., Kysenius, K., Kosunen, M., Lehmus, L., & Murtola, T. J. (2026). Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014–2022 in Pirkanmaa, Finland—an observational study. Therapeutic Advances in Urology, 18. https://doi.org/10.1177/17562872261451289
Vancouver
Moisander M, Hölsä O, Teittinen K, Kysenius K, Kosunen M, Lehmus L, et al. Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014–2022 in Pirkanmaa, Finland—an observational study. Therapeutic Advances in Urology. 2026;18. doi:10.1177/17562872261451289
BibTeX
@article{Moisander2026,
author = {Moisander, Mikko and Hölsä, Olivia and Teittinen, Kaisa and Kysenius, Kai and Kosunen, Mikko and Lehmus, Leena and Murtola, Teemu J},
title = {Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014–2022 in Pirkanmaa, Finland—an observational study},
journal = {Therapeutic Advances in Urology},
year = {2026},
volume = {18},
doi = {10.1177/17562872261451289}
}
EUVIMED